v3.26.1
Segment Reporting
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company manages its business activities on a consolidated basis and has one reportable segment relating to the research and development of novel therapies. The Chief Executive Officer, who serves as the Company’s chief operating decision maker (“CODM”), is responsible for the overall supervision, direction, and management of the business and its officers.
The CODM reviews net loss, as reported in the condensed consolidated statements of operations and comprehensive loss, as well as the progress of the Company’s program(s). The CODM does not review assets in evaluating the results of the segment, and therefore, such information is not presented. All long-lived assets owned by the Company are located in the United States. The accounting policies of the segment are the same as those described in Note 2.
The following table is a summary of the segment and consolidated net loss, including significant segment expenses for the three months ended March 31, 2026 and 2025 (in thousands):
Three Months Ended March 31,
20262025
AXN-2510$659 $4,715 
Other program expenses(1)
10 656 
General and administrative(2)
5,338 8,611 
Restructuring charges992 16,082 
Depreciation11 498 
Interest income(678)(1,175)
Interest expense1,552 1,098 
Gain on contract termination(1,620)— 
Other income, net(2,060)(2,285)
Segment and consolidated net loss$4,204 $28,200 
______________________________________________________________
(1)    Other program expenses consist of costs related to the Company’s past development of its CoStAR-TIL technology.
(2)    Depreciation expense is removed from “General and administrative” and is disclosed separately.